Antibody-assisted target identification reveals afatinib, an EGFR covalent inhibitor, down-regulating ribonucleotide reductase

Afatinib, used for the first-line treatment of non-small-cell lung carcinoma (NSCLC) patients with distinct epidermal growth factor receptor (EGFR) mutations, inactivates EGFR by mimicking ATP structure and forming a covalent adduct with EGFR. We developed a method to unravel potential targets of af...

Descripción completa

Detalles Bibliográficos
Autores principales: Yu, Cheng-Han, Chou, Chi-Chi, Tu, Hsin-Fang, Huang, Wei-Chieh, Ho, Ya-Yeh, Khoo, Kay-Hooi, Lee, Ming-Shyue, Chang, Geen-Dong
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Impact Journals LLC 2018
Materias:
Research Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5940374/
https://www.ncbi.nlm.nih.gov/pubmed/29765556
http://dx.doi.org/10.18632/oncotarget.25177

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5940374/
https://www.ncbi.nlm.nih.gov/pubmed/29765556
http://dx.doi.org/10.18632/oncotarget.25177

Ejemplares similares